Vivalyx Secures Major Funding Boost for Organ Revitalization Technology
Deal News | Feb 19, 2025 | Brightlands Venture Partners
Organ vitality tech startup Vivalyx has received a €2.5 million grant from the European Innovation Council (EIC) Accelerator and a pre-commitment for an additional €6 million in equity investment. This funding aims to expedite the market approval of Omnisol, their proprietary organ perfusate designed to replace blood in donor organs. With regulatory approval for its use in body-temperature perfusion, Omnisol represents a potential breakthrough in organ preservation and revitalization. Preclinical trials have demonstrated improved outcomes compared to traditional methods involving blood or blood-based solutions. Furthermore, Omnisol has promising applications beyond transplants, such as in autotransplantation procedures for some cancer treatments. The funding will also facilitate team expansion and enhance Vivalyx's clinical and commercial capabilities. The investment is a pivotal development for the company led by Dr. Andreas Schumacher, establishing the importance and potential impact of their technology on organ transplant and preservation.
Sectors
- Biotechnology
- Healthcare
- Venture Capital
Geography
- Germany – Vivalyx is based in Aachen, Germany, and it is where their innovative technology is being developed and pursued.
- Netherlands – Brightlands Venture Partners is based in the Netherlands and invests in companies across the region, including Germany, which reflects its geographical investment focus.
- European Union – The European Innovation Council (EIC) Accelerator that awarded the grant to Vivalyx is an EU initiative, reflecting the broader geographical scope of the funding.
Industry
- Biotechnology – Vivalyx operates in the biotechnology sector, focusing on developing technologies for organ preservation and revitalization.
- Healthcare – The development of Omnisol is centered around improving healthcare outcomes in organ transplantation and certain complex medical treatments.
- Venture Capital – Brightlands Venture Partners, a VC firm, is investing in early-stage health startups like Vivalyx, showcasing its role in funding innovation in the healthcare sector.
Financials
- €2.5M – Grant received from the EIC Accelerator for Vivalyx's project.
- €6M – Pre-commitment for an equity investment in Vivalyx.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Vivalyx GmbH | Target Company | Company | A startup developing organ revitalization technology, specifically through Omnisol, a blood-replacing donor organ perfusate. |
| Brightlands Venture Partners | Investor | Company | A venture capital firm focusing on health and sustainability startups in the Netherlands, Germany, and Belgium. |
| European Innovation Council (EIC) Accelerator | Funder | Government | A major EU initiative providing funding and support to innovative startups across Europe. |
| Dr. Andreas Schumacher | CEO | People | CEO of Vivalyx, leading the development of Omnisol and spearheading the company's mission. |